Notice of Proposed Settlement Agreement Under the Oil Pollution Act, 2675-2676 [2018-00811]
Download as PDF
<![CDATA[
2675
Federal Register / Vol. 83, No. 12 / Thursday, January 18, 2018 / Notices
Controlled substance
Drug code
Dihydrocodeine ................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................
Hydrocodone ...................................................................................................................................................................
Levomethorphan ..............................................................................................................................................................
Levorphanol .....................................................................................................................................................................
Isomethadone ..................................................................................................................................................................
Meperidine .......................................................................................................................................................................
Meperidine intermediate-A ..............................................................................................................................................
Meperidine intermediate-B ..............................................................................................................................................
Meperidine intermediate-C ..............................................................................................................................................
Methadone .......................................................................................................................................................................
Methadone intermediate ..................................................................................................................................................
Metopon ...........................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ..............................................................................................................
Morphine ..........................................................................................................................................................................
Thebaine ..........................................................................................................................................................................
Dihydroetorphine .............................................................................................................................................................
Levo-alphacetylmethadol .................................................................................................................................................
Oxymorphone ..................................................................................................................................................................
Noroxymorphone .............................................................................................................................................................
Phenazocine ....................................................................................................................................................................
Thiafentanil ......................................................................................................................................................................
Piminodine .......................................................................................................................................................................
Racemethorphan .............................................................................................................................................................
Racemorphan ..................................................................................................................................................................
Alfentanil ..........................................................................................................................................................................
Remifentanil .....................................................................................................................................................................
Sufentanil .........................................................................................................................................................................
Carfentanil .......................................................................................................................................................................
Tapentadol .......................................................................................................................................................................
Bezitramide ......................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................
Moramide-intermediate ....................................................................................................................................................
The company plans to manufacture
small quantities of the listed controlled
substances in bulk for distribution to its
customers.
Administration, Attention: DEA Federal
Register Representative/DRW, 8701
Morrissette Drive, Springfield, Virginia
22152.
Dated: January 5, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
SUPPLEMENTARY INFORMATION:
[FR Doc. 2018–00710 Filed 1–17–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Alcami
Wisconsin Corporation
sradovich on DSK3GMQ082PROD with NOTICES
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before March 19, 2018.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
DATES:
VerDate Sep<11>2014
18:27 Jan 17, 2018
Jkt 244001
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on July 4,
2017, Alcami Wisconsin Corporation,
W130 N10497 Washington Drive,
Germantown, Wisconsin 53022 applied
to be registered as a bulk manufacturer
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
9120
9143
9150
9170
9180
9190
9193
9210
9220
9226
9230
9232
9233
9234
9250
9254
9260
9273
9300
9333
9334
9648
9652
9668
9715
9729
9730
9732
9733
9737
9739
9740
9743
9780
9800
9801
9802
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
of thebaine (9333), a basic class of
controlled substance listed in schedule
II.
The company states they plan to
conduct clinical trials.
Dated: January 5, 2018.
Susan A. Gibson,
Deputy Assistant Administrator.
[FR Doc. 2018–00709 Filed 1–17–18; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Notice of Proposed Settlement
Agreement Under the Oil Pollution Act
On January 9, 2018, a fully-executed
proposed Settlement Agreement was
received by the Department of Justice,
among the United States on behalf of the
U.S. Department of the Interior, U.S.
Fish and Wildlife Service (‘‘FWS’’), the
State of Georgia, on behalf of the
Georgia Department of Natural
Resources (‘‘GDNR’’), and Fukunaga
Kaiun Co., Ltd., a Japanese company
that was the former operator of the
Motor Vessel Fortune Epoch in
November 2004.
E:\FR\FM\18JAN1.SGM
18JAN1
2676
Federal Register / Vol. 83, No. 12 / Thursday, January 18, 2018 / Notices
The Settlement Agreement resolves
certain claims by the FWS and GDNR
for natural resource damages resulting
from a November 2004 oil spill from the
M/V Fortune Epoch near Tybee Island,
Georgia. The Settlement Agreement
requires Fukunaga Kaiun Co., Ltd. to
pay $775,000 to pay the FWS and
GDNR, the natural resource trustees
(‘‘Trustees’’) for this matter, for past
assessment costs and for the joint
benefit and use of the Trustees to pay
for Trustee-sponsored natural resource
restoration efforts.
The publication of this notice opens
a period for public comment on the
proposed Settlement Agreement.
Comments should be addressed to the
Assistant Attorney General,
Environment and Natural Resources
Division, and should refer to United
States and State of Georgia’s Settlement
Agreement with Fukunaga Kaiun Co.
Ltd., D.J. Ref. No. 90–5–1–1–10825. All
comments must be submitted no later
than thirty (30) days after the
publication date of this notice.
Comments may be submitted either by
email or by mail:
To submit
comments:
Send them to:
By email .......
pubcomment-ees.enrd@
usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington,
D.C. 20044–7611.
By mail .........
sradovich on DSK3GMQ082PROD with NOTICES
During the public comment period,
the proposed Settlement Agreement
may be examined and downloaded at
this Justice Department website: https://
www.justice.gov/enrd/consent-decrees.
We will provide a paper copy of the
proposed Settlement Agreement upon
written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $4 (25 cents per page reproduction
cost) payable to the United States
Treasury.
Henry S. Friedman,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2018–00811 Filed 1–17–18; 8:45 am]
BILLING CODE 4410–15–P
VerDate Sep<11>2014
18:27 Jan 17, 2018
Jkt 244001
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2011–0027]
Respiratory Protection Standard;
Extension of the Office of Management
and Budget’s (OMB) Approval of
Information Collection (Paperwork)
Requirements
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Request for public comments.
AGENCY:
OSHA solicits public
comments concerning its proposal to
extend OMB approval of the
information collection requirements
specified by the Respiratory Protection
Standard.
DATES: Comments must be submitted
(postmarked, sent, or received) by
March 19, 2018.
ADDRESSES: Electronically: You may
submit comments and attachments
electronically at https://
www.regulations.gov, which is the
Federal eRulemaking Portal. Follow the
instructions online for submitting
comments.
Facsimile: If your comments,
including attachments, are not longer
than 10 pages you may fax them to the
OSHA Docket Office at (202) 693–1648.
Mail, hand delivery, express mail,
messenger, or courier service: When
using this method, you must submit a
copy of your comments and attachments
to the OSHA Docket Office, Docket No.
OSHA–2011–0027, U.S. Department of
Labor, Occupational Safety and Health
Administration, Room N–3653, 200
Constitution Avenue NW, Washington,
DC 20210. Deliveries (hand, express
mail, messenger, and courier service)
are accepted during the Docket Office’s
normal business hours, 10:00 a.m. to
3:00 p.m., ET.
Instructions: All submissions must
include the Agency name and the OSHA
docket number (OSHA–2011–0027) for
the Information Collection Request
(ICR). All comments, including any
personal information you provide, are
placed in the public docket without
change, and may be made available
online at https://www.regulations.gov.
For further information on submitting
comments, see the ‘‘Public
Participation’’ heading in the section of
this notice titled SUPPLEMENTARY
INFORMATION.
Docket: To read or download
comments or other material in the
docket, go to https://www.regulations.gov
or the OSHA Docket Office at the above
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
address. All documents in the docket
(including this Federal Register notice)
are listed in the https://
www.regulations.gov index; however,
some information (e.g., copyrighted
material) is not publicly available to
read or download from the website. All
submissions, including copyrighted
material, are available for inspection
and copying at the OSHA Docket Office.
You may also contact Theda Kenney at
the address below to obtain a copy of
the ICR.
FOR FURTHER INFORMATION CONTACT:
Charles McCormick or Theda Kenney,
Directorate of Standards and Guidance,
OSHA, U.S. Department of Labor, Room
N–3609, 200 Constitution Avenue NW.,
Washington, DC 20210; telephone (202)
693–2222.
SUPPLEMENTARY INFORMATION:
I. Background
The Department of Labor, as part of its
continuing effort to reduce paperwork
and respondent (i.e., employer) burden,
conducts a preclearance consultation
program to provide the public with an
opportunity to comment on proposed
and continuing information collection
requirements in accordance with the
Paperwork Reduction Act of 1995
(PRA–95) (44 U.S.C. 3506(c)(2)(A)). This
program ensures that information is in
the desired format, reporting burden
(time and costs) is minimal, collection
instruments are clearly understood, and
OSHA’s estimate of the information
collection burden is accurate. The
Occupational Safety and Health Act of
1970 (the OSH Act) (29 U.S.C. 651 et
seq.) authorizes information collection
by employers as necessary or
appropriate for enforcement of the Act
or for developing information regarding
the causes and prevention of
occupational injuries, illnesses, and
accidents (29 U.S.C. 657). The OSH Act
also requires that OSHA obtain such
information with minimum burden
upon employers, especially those
operating small businesses, and to
reduce to the maximum extent feasible
unnecessary duplication of efforts in
obtaining information (29 U.S.C. 657).
The Respiratory Protection Standard
(29 CFR 1910.134; hereafter, ‘‘the
Standard’’) contains information
collection requirements that require
employers to: develop a written
respirator program; conduct worker
medical evaluations and provide followup medical evaluations to determine the
worker’s ability to use a respirator;
provide the physician or other licensed
healthcare professional with
information about the worker’s
respirator and the conditions under
E:\FR\FM\18JAN1.SGM
18JAN1
]]>Agencies
[Federal Register Volume 83, Number 12 (Thursday, January 18, 2018)]
[Notices]
[Pages 2675-2676]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00811]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Notice of Proposed Settlement Agreement Under the Oil Pollution
Act
On January 9, 2018, a fully-executed proposed Settlement Agreement
was received by the Department of Justice, among the United States on
behalf of the U.S. Department of the Interior, U.S. Fish and Wildlife
Service (``FWS''), the State of Georgia, on behalf of the Georgia
Department of Natural Resources (``GDNR''), and Fukunaga Kaiun Co.,
Ltd., a Japanese company that was the former operator of the Motor
Vessel Fortune Epoch in November 2004.
[[Page 2676]]
The Settlement Agreement resolves certain claims by the FWS and
GDNR for natural resource damages resulting from a November 2004 oil
spill from the M/V Fortune Epoch near Tybee Island, Georgia. The
Settlement Agreement requires Fukunaga Kaiun Co., Ltd. to pay $775,000
to pay the FWS and GDNR, the natural resource trustees (``Trustees'')
for this matter, for past assessment costs and for the joint benefit
and use of the Trustees to pay for Trustee-sponsored natural resource
restoration efforts.
The publication of this notice opens a period for public comment on
the proposed Settlement Agreement. Comments should be addressed to the
Assistant Attorney General, Environment and Natural Resources Division,
and should refer to United States and State of Georgia's Settlement
Agreement with Fukunaga Kaiun Co. Ltd., D.J. Ref. No. 90-5-1-1-10825.
All comments must be submitted no later than thirty (30) days after the
publication date of this notice. Comments may be submitted either by
email or by mail:
------------------------------------------------------------------------
To submit comments: Send them to:
------------------------------------------------------------------------
By email............................ [email protected].
By mail............................. Assistant Attorney General, U.S.
DOJ--ENRD, P.O. Box 7611,
Washington, D.C. 20044-7611.
------------------------------------------------------------------------
During the public comment period, the proposed Settlement Agreement
may be examined and downloaded at this Justice Department website:
https://www.justice.gov/enrd/consent-decrees. We will provide a paper
copy of the proposed Settlement Agreement upon written request and
payment of reproduction costs. Please mail your request and payment to:
Consent Decree Library, U.S. DOJ--ENRD, P.O. Box 7611, Washington, DC
20044-7611.
Please enclose a check or money order for $4 (25 cents per page
reproduction cost) payable to the United States Treasury.
Henry S. Friedman,
Assistant Section Chief, Environmental Enforcement Section, Environment
and Natural Resources Division.
[FR Doc. 2018-00811 Filed 1-17-18; 8:45 am]
BILLING CODE 4410-15-P
